These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23381692)

  • 21. [Clinical significance of interactions between clopidogrel and proton pump inhibitors].
    Kubica A; Koziński M; Grześk G; Goch A
    Kardiol Pol; 2011; 69(6):610-6. PubMed ID: 21678305
    [No Abstract]   [Full Text] [Related]  

  • 22. Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
    Perry E
    Am J Health Syst Pharm; 2011 Mar; 68(6):529-32. PubMed ID: 21378302
    [No Abstract]   [Full Text] [Related]  

  • 23. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
    Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
    J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
    Kenngott S; Olze R; Kollmer M; Bottheim H; Laner A; Holinski-Feder E; Gross M
    Eur J Med Res; 2010 May; 15(5):220-4. PubMed ID: 20562062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Kagami T; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K; Umemura K
    J Thromb Thrombolysis; 2017 Apr; 43(3):333-342. PubMed ID: 27981489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.
    El-Halabi MM; Zgheib N; Mansour NM; Malli A; Ghaith OA; Mahfouz R; Alam S; Sharara AI
    J Cardiovasc Pharmacol; 2013 Jul; 62(1):41-9. PubMed ID: 23474843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
    Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In brief: poor metabolizers of clopidogrel (plavix).
    Med Lett Drugs Ther; 2010 May; 52(1337):33. PubMed ID: 20431520
    [No Abstract]   [Full Text] [Related]  

  • 29. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.
    Ellis KJ; Stouffer GA; McLeod HL; Lee CR
    Pharmacogenomics; 2009 Nov; 10(11):1799-817. PubMed ID: 19891556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis.
    Biswas M; Rahaman S; Biswas TK; Ibrahim B
    Int J Clin Pharm; 2021 Oct; 43(5):1360-1369. PubMed ID: 33774763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
    Angiolillo DJ; Gibson CM; Cheng S; Ollier C; Nicolas O; Bergougnan L; Perrin L; LaCreta FP; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
    Mega JL; Hochholzer W; Frelinger AL; Kluk MJ; Angiolillo DJ; Kereiakes DJ; Isserman S; Rogers WJ; Ruff CT; Contant C; Pencina MJ; Scirica BM; Longtine JA; Michelson AD; Sabatine MS
    JAMA; 2011 Nov; 306(20):2221-8. PubMed ID: 22088980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proton pump inhibitors and clopidogrel.
    Gaglia MA; Waksman R
    Cardiovasc Ther; 2010 Jun; 28(3):169-76. PubMed ID: 20345494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects.
    Fontana P; Hulot JS; De Moerloose P; Gaussem P
    J Thromb Haemost; 2007 Oct; 5(10):2153-5. PubMed ID: 17697139
    [No Abstract]   [Full Text] [Related]  

  • 36. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
    Zabalza M; Subirana I; Sala J; Lluis-Ganella C; Lucas G; Tomás M; Masiá R; Marrugat J; Brugada R; Elosua R
    Heart; 2012 Jan; 98(2):100-8. PubMed ID: 21693476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dilemma between gastroprotection and cardiovascular prevention].
    Venerito M; Kandulski A; Malfertheiner P
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2193-8. PubMed ID: 20979006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.
    Fernando H; Dart AM; Peter K; Shaw JA
    Thromb Haemost; 2011 Jun; 105(6):933-44. PubMed ID: 21544314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.